New drug combo shows promise for Tough-to-Treat prostate cancer
Disease control
Completed
This Phase 2 trial tested an immunotherapy drug called vudalimab, either by itself or combined with standard chemotherapy or targeted therapy, in 72 men with metastatic castration-resistant prostate cancer that had worsened after prior treatments. The main goal was to check safet…
Phase: PHASE2 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC